Biotechs Roaring Back: Do They Sense A Deal? Update -1 ABBV/PCYC
Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug Imbruvica for chronic...
Mid Cap Emerging Biopharmaceutical Companies: Valuations Do Matter for M&A
Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there” for the acquisition of...
SierraSnow Blog 2/27-3/3/15…. More Snowpack
More snow coming this weekend: Jet Stream in Place earth :: an animated map of global wind, weather, and ocean conditions National Maps – NOAA’s National Weather Service 814prcp.new.gif 719×759 pixels Colder wetter bringing 12 in.+ Mammoth Lakes Weather brought to you by Howard...
Rayno Biopharmaceutical Stocks: PCYC Buzz Drive Biotechs Higher… Update-1
2/27 Friday After a big February biotechs turned red today with major ETFs off about 1%. In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif below: ALNY, BMRN, INCY, MDVN,...
Rayno Dx and Tools: Update EXAS
Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health...